HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Single versus multiple dose intravenous immunoglobulin in combination with LED phototherapy in the treatment of ABO hemolytic disease in neonates.

Abstract
Intravenous immunoglobulin (IVIG) has been found to decrease hemolysis in neonatal jaundice due to blood group incompatibility, but a consensus on its usage has not been reached. We conducted a study to compare single versus multiple dose of IVIG in combination with light emitting diode (LED) phototherapy in patients with neonatal jaundice secondary to ABO blood incompatibility, and compared the efficacy of these treatments with that in a group of patients who received LED phototherapy solely. Thirty-nine term neonates with ABO blood group incompatibility were enrolled in the study. Group I received one dose of IVIG (1 g/kg) and LED phototherapy, and group II two doses of IVIG (1 g/kg) and LED phototherapy, whereas group III received LED phototherapy only. In group I, exchange transfusion was performed in one patient (6%) and in group II in one patient (10%). In the control group, none of the patients required exchange transfusion. Duration of LED phototherapy was 4.3 ± 0.7 days in group I + II (IVIG group), 3.9 ± 0.6 days in group III (P = 0.06). Lowest hematocrit level in group I + II was 35.0 ± 7.8 and group III was 38.9 ± 4.2, this was statistically significant (P = 0.034). IVIG therapy, single or multiple, did not affect exchange transfusion, need of erythrocyte transfusion and hospitalization time when used in combination with LED phototherapy in the treatment of ABO hemolytic jaundice in neonates.
AuthorsGamze Demirel, Melek Akar, Istemi Han Celik, Omer Erdeve, Nurdan Uras, Serife Suna Oguz, Ugur Dilmen
JournalInternational journal of hematology (Int J Hematol) Vol. 93 Issue 6 Pg. 700-703 (Jun 2011) ISSN: 1865-3774 [Electronic] Japan
PMID21617887 (Publication Type: Journal Article)
Chemical References
  • Immunoglobulins, Intravenous
  • Immunologic Factors
Topics
  • Blood Transfusion, Autologous
  • Erythroblastosis, Fetal (drug therapy, therapy)
  • Erythrocyte Transfusion
  • Exchange Transfusion, Whole Blood
  • Female
  • Humans
  • Immunoglobulins, Intravenous (administration & dosage)
  • Immunologic Factors (administration & dosage)
  • Infant
  • Infant, Newborn
  • Intensive Care Units, Neonatal
  • Jaundice, Neonatal (therapy)
  • Male
  • Phototherapy

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: